Loomis, Sayles & Company’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $159M | Sell |
|
|||||
|
2025
Q1 | $134M | Sell |
|
|||||
|
2024
Q4 | $118M | Sell |
|
|||||
|
2024
Q3 | $144M | Sell |
|
|||||
|
2024
Q2 | $138M | Sell |
|
|||||
|
2024
Q1 | $87M | Sell |
|
|||||
|
2023
Q4 | $117M | Sell |
|
|||||
|
2023
Q3 | $111M | Sell |
|
|||||
|
2023
Q2 | $123M | Sell |
|
|||||
|
2023
Q1 | $132M | Sell |
|
|||||
|
2022
Q4 | $169M | Sell |
|
|||||
|
2022
Q3 | $150M | Sell |
|
|||||
|
2022
Q2 | $121M | Sell |
|
|||||
|
2022
Q1 | $142M | Sell |
|
|||||
|
2021
Q4 | $169M | Buy |
|
|||||
|
2021
Q3 | $183M | Buy |
|
|||||
|
2021
Q2 | $160M | Buy |
|